Late Breaking Clinical Trial submissions are now closed
What is Late Breaking Clinical Trials?
Late Breaking Clinical Trials is an always-popular session where speakers present the results of a new research in heart failure. Featured on a plenary session stage, Spotlight on Late Breaking Clinical Trials provides exposure and recognition for major randomized trials and registries that will likely have a significant impact on clinical practice or result in significant advances in the field.
Featuring the Following:
Sunday, October 8
- Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure with Preserved Ejection Fraction: Primary Results of the REBALANCE-HF Randomized Trial
- Effects Of Semaglutide Across the Range Of Left Ventricular Ejection Fraction in Obesity Phenotype of Heart Failure with Preserved Ejection Fraction: The STEP-HFpEF Trial
- Primary Results of the Prospective Single Arm Trial of Hemodynamic-Guided Management of Heart Failure (GUIDE-HF)
- Efficacy and Safety of Sacubitril/valsartan in Patients Hospitalized with Heart Failure: A Prespecified, Pooled Individual Patient-level Analysis of PIONEER-HF and PARAGLIDE-HF
- Autonomic Regulation Therapy to Improve Symptoms and Clinical Outcomes in Patients with Heart Failure And Reduced Ejection Fraction (ANTHEM-HFrEF) Pivotal Study Results
Monday, October 9
- Revisiting Omecamtiv Mecarbil
- Long-Term Effects Of Atrial Shunt Device On Cardiac Structure And Function In Heart Failure With Preserved And Mildly Reduced Ejection Fraction: Results From The REDUCE LAP-HF II Randomized Clinical Trial
- Safety Indicators In Patients Receiving High-intensity Care After Acute Heart Failure Admission: The STRONG-HF Trial
- Final Analysis Of Safety And Exploratory Echo Data In A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study To Evaluate JK07 In Subjects With Heart Failure With Reduced Ejection Fraction
- Effect Of Trientine-hydrochloride In Heart Failure With Lower Left Ventricular Ejection Fraction: The TRACER-HF Trial
Abstracts accepted are embargoed for release until the time of presentation at the Heart Failure Society of America's Annual Scientific Meeting.
The standard is that any company can announce at any time the following:
- Announcement that trial is completed
- That results will be presented at so and so date in such and such a meeting
- What did the trial assess - basic design, questions, study population, interventions, etc.
NO RESULTS AT ALL OR ANY HINTS OF RESULTS INDIRECTLY
Clinical trials accepted for presentation will be:
- Presented during the Late Breaking Clinical Trials session
- Accepted Late Breaking Clinical Trials abstracts will be published in an issue of the Journal of Cardiac Failure after the Annual Scientific Meeting. Authors will have the ability to update the submitted abstract prior to publication. JCF encourages all accepted Late Breaking Clinical Trials to submit full papers for further consideration
All late breaking data is embargoed until the day of Late Breaking Clinical Trials session.
If an accepted late breaking clinical trial abstract was submitted and accepted for general abstract/poster presentation at the HFSA Annual Scientific Meeting, it needs to be withdrawn by August 25, 2023.